Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease

Eppie M Yiu1,2,3, Paula Bray4,5, Jonathan Baets6,7,8

  • 1Neurology Department, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia eppie.yiu@rch.org.au.

Insights

New guidelines offer evidence-based recommendations for managing childhood Charcot-Marie-Tooth disease (CMT), aiming to standardize care for this common inherited neuropathy. These guidelines address key challenges faced by pediatric patients with CMT.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Charcot-Marie-Tooth disease (CMT) is the most prevalent inherited neuropathy, frequently diagnosed in childhood.
  • Optimal management guidelines for common CMT-related issues in children and adults are currently lacking.
  • The Paediatric CMT Best Practice Guidelines Consortium was established to address this gap.

Purpose of the Study:

  • To develop evidence and consensus-based recommendations for the clinical management of pediatric and adolescent patients with CMT.
  • To promote optimal and standardized global care for children with CMT.
  • To provide practical guidance for managing common clinical problems in pediatric CMT.

Main Methods:

  • Systematic reviews addressing 10 clinical questions.
  • Modified Delphi methodology with an international clinician panel for consensus building.
  • Application of the GRADE approach to assess evidence quality and formulate recommendations.

Main Results:

  • The guideline comprises 3 evidence-based and 31 consensus-based recommendations.
  • Recommendations cover management of muscle weakness, balance, mobility, sensory symptoms, cramps, upper limb function, respiratory issues, joint range of motion, and non-surgical deformity management.
  • Areas of non-consensus highlight practice variations and the need for further research.

Conclusions:

  • This clinical practice guideline offers practical, implementable guidance for managing common pediatric CMT issues.
  • It advocates for enhanced access to multidisciplinary care for children with CMT.
  • Effective dissemination and implementation are crucial for widespread application across healthcare settings.
Abstract

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
234
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
83
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
58
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
44